Immunovaccine begins Phase Ib/II of HPV-related cancer vaccine DPX-E7

In April, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) said that the Dana-Farber Cancer Institute (Boston, Mass.) began a Phase Ib/II trial of the biotech’s DPX-E7 plus low-dose cyclophosphamide in 44 patients who are HLA-A*02-positive with incurable HPV 16-related oropharyngeal, cervical and anal cancers.

The open-label, U.S. trial will evaluate 2 priming doses of DPX-E7 given 3 weeks apart followed by a booster dose every 8 weeks until clinical progression. The primary endpoints are safety and changes in CD8+ T cells in peripheral blood and tumor tissue. Secondary endpoints include overall response rate (ORR), overall survival (OS) and progression-free survival (PFS)...